BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 30267414)

  • 1. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method).
    Hosokawa M; Kashiwagi H; Nakayama K; Sakuragi M; Nakao M; Morikawa T; Kiyokawa T; Aochi H; Nagamine K; Shibayama H; Tomiyama Y
    Transfusion; 2018 Dec; 58(12):3003-3013. PubMed ID: 30267414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resolving the daratumumab interference with blood compatibility testing.
    Chapuy CI; Nicholson RT; Aguad MD; Chapuy B; Laubach JP; Richardson PG; Doshi P; Kaufman RM
    Transfusion; 2015 Jun; 55(6 Pt 2):1545-54. PubMed ID: 25764134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficient neutralization of daratumumab in pretransfusion samples using a novel recombinant monoclonal anti-idiotype antibody.
    Aung F; Spencer J; Potter D; Pham TD; Farooqui N; Platt KR; Zayat R; Oliveira M; Smeland-Wagman R; Petersen E; Kaufman RM
    Transfusion; 2022 Aug; 62(8):1511-1518. PubMed ID: 35866570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New method for overcoming the interference produced by anti-CD38 monoclonal antibodies in compatibility testing.
    Izaguirre EC; Del Mar Luis-Hidalgo M; González LL; Castaño CA
    Blood Transfus; 2020 Jul; 18(4):290-294. PubMed ID: 32530397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing.
    Chapuy CI; Aguad MD; Nicholson RT; AuBuchon JP; Cohn CS; Delaney M; Fung MK; Unger M; Doshi P; Murphy MF; Dumont LJ; Kaufman RM;
    Transfusion; 2016 Dec; 56(12):2964-2972. PubMed ID: 27600566
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing.
    Chinoca Ziza KN; Paiva TA; Mota SR; Dezan MR; Schmidt LC; Brunetta DM; Ricci G; Basques FV; Barroso-Duarte F; Rocha V; Mendrone-Junior A; Dinardo CL
    Transfusion; 2019 May; 59(5):1827-1835. PubMed ID: 30779172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blood component administration to multiple myeloma patients treated with daratumumab: suggesting a novel approach with use of 0.1 M dithiothreitol.
    Pandey P; Setya D; Kaul E; Ranjan S; Singh MK; Shankar A
    Immunohematology; 2020 Dec; 36(4):157-165. PubMed ID: 33544622
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Mercaptoethanol (2-ME)-based IATs or Polybrene method mitigates the interference of daratumumab on blood compatibility tests.
    Zhou Y; Chen L; Jiang T; Fan L; Lei H; Wang Y; Heililahong H; Mi J; Du D; Miao T; Xia R; Wang X; Xiang D; Cai X; Tang X
    Hematology; 2021 Dec; 26(1):365-370. PubMed ID: 33971806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of an in-house trypsin-based method to resolve the interference of daratumumab.
    Ibeh N; Baine I; Rudon LF; Lomas-Francis C; Jhang JS; Galdon P; Westhoff CM; Velliquette RW; Arinsburg SA
    Transfusion; 2021 Oct; 61(10):3000-3007. PubMed ID: 34472116
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Challenges of Daratumumab in Transfusion Medicine.
    Dizon MF
    Lab Med; 2017 Feb; 48(1):6-9. PubMed ID: 27794527
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extending shelf life of dithiothreitol-treated panel RBCs to 28 days.
    Sigle JP; Mihm B; Suna R; Bargetzi M
    Vox Sang; 2018 May; 113(4):397-399. PubMed ID: 29512161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A newly devised flow cytometric antibody binding assay helps evaluation of dithiothreitol treatment for the inactivation of CD38 on red blood cells.
    Furumaki H; Takeshita A; Ohto H; Yamada C; Fujihara H; Ishizuka K; Shibata H; Shinba T; Nemoto N; Ino K; Ozawa A; Watanabe H; Kawabata K; Obata Y
    Vox Sang; 2021 Jul; 116(6):725-734. PubMed ID: 33314130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Daratumumab Interference in Pretransfusion Testing Is Overcome by Addition of Daratumumab Fab Fragments to Patients' Plasma.
    Werle E; Ziebart J; Wasmund E; Eske-Pogodda K
    Transfus Med Hemother; 2019 Dec; 46(6):423-430. PubMed ID: 31933572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Better resolving of anti-CD38 antibody interference with blood compatibility testing by using manual polybrene method compared with dithiothreitol-pretreatment indirect antiglobulin test.
    Feng CC; Chang CW; Lien ZY; Lin JA; Chen TT; Yeh SP
    J Clin Lab Anal; 2023 Apr; 37(8):e24891. PubMed ID: 37161608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daudi cell stroma: An alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing.
    Tremblay T; Branch DR; Loubaki L
    Transfusion; 2020 Sep; 60(9):2090-2096. PubMed ID: 32632934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies.
    Baig NA; Dukek BA; Falbo DK; Wakefield LL; DiGuardo MA; Bobr A; Kreuter JD; Gandhi MJ
    Vox Sang; 2021 Jan; 116(1):116-122. PubMed ID: 32797679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mitigation of therapeutic anti-CD38 antibody interference with fab fragments: How well does it perform?
    Habicht CP; Ridders M; Grueger D; Adolph S; Immenschuh S; Schneeweiss C
    Transfusion; 2023 Apr; 63(4):808-816. PubMed ID: 36707937
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of clinical application of anti-CD38 and anti-CD47 monoclonal antibodies on blood group detection and transfusion therapy and treatment.
    Du C; Sui W; Huang H; Zhang Y; Ding X; Gao C; Wang Y
    Leuk Res; 2022 Nov; 122():106953. PubMed ID: 36182722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pre-Transfusion Testing and Transfusion Strategy in Patients with Multiple Myeloma after Daratumumab Treatment].
    Fang XM; Guo ZW; Yang JQ; Yang B; Xiao YH; Liu Y; Xu ML
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1595-1600. PubMed ID: 34627446
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of Daratumumab on transfusion service costs.
    Cushing MM; DeSimone RA; Goel R; Hsu YS; Parra P; Racine-Brzostek SE; Degtyaryova D; Lo DT; Morrison M; Crowley KM; Rossi A; Vasovic LV
    Transfusion; 2019 Apr; 59(4):1252-1258. PubMed ID: 30620407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.